Conference Day 1

All times in EDT

8:30 am Welcome Coffee & Networking

8:50 am Chair’s Opening Remarks

  • Jason Faris Senior Clinical Program Leader, Novartis Institutes for BioMedical Research

Leveraging Mechanistic Insights of Hippo Pathway Regulation in Disease

9:00 am Reviewing & Outlining the Mechanisms of Hippo Pathway Regulation

  • Kun-Liang Guan Distinguished Professor Department of Pharmacology, University of California San Diego

Synopsis

  • Mechanisms of Hippo pathway regulation
  • Discussing the functional interplay between the Hippo and estrogen receptor
  • Outlining phosphoinositides in Hippo pathway regulation

9:30 am Control of Transcription by the Hippo Pathway

  • Kieran Harvey Group Leader, Peter MacCallum Cancer Centre & Monash University

Synopsis

  • How does Hippo signaling regulate transcriptional regulatory proteins?
  • How do Hippo pathway transcription factors regulate gene expression?
  • How do chemical modulate Hippo signaling?

10:00 am Epithelioid Hemangioendothelioma as a Paradigm for Hippo Pathway Dysregulation

  • Brian Rubin Chair, Pathology & Laboratory Medicine, The Cleveland Clinic

Synopsis

  • TAZ-CAMTA1 gene fusion is only genetic alteration in epithelioid hemangioendothelioma
  • TAZ-CAMTA1 fusion oncoprotein is a well credentialed target for TEAD inhibitors
  • Epithelioid hemangioendothelioma genetically engineered mouse model is an excellent model for testing TAZ/TEAD inhibitors

10:30 am Morning Break & Speed Networking

Synopsis

As the community of individuals working to drug the Hippo pathway is united, this valuable session will ensure you can reconnect with your peers to make new and lasting connections, as all attendees will have the opportunity to meet and network with academic and industry colleagues

11:30 am Learnings from Hippo Signaling Crosstalk – Considering Upstream & Downstream Responses & How can we Leverage this Crosstalk for Intervention within Therapeutic Resistance

  • WanJin Hong Professor & Executive Director, Institute of Molecular and Cell Biology, A*STAR
  • Brian Rubin Chair, Pathology & Laboratory Medicine, The Cleveland Clinic
  • Olivier Venier Group Leader, Medicinal Chemistry, Integrated Drug Discovery, Sanofi

Synopsis

Roundtable Discussion

12:30 pm Lunch Break & Networking

Drugging the Hippo Pathway in Oncology & Beyond – Leveraging the TEAD Druggable Pocket

1:30 pm Discovery & Development of Novel Covalent TEAD Inhibitors

Synopsis

  • Introduction to IMTAC screening platform and BridGene’s covalent library
  • IMTAC screening identifies three distinct TEAD ligands
  • Functional and biochemical characterization of novel TEAD inhibitors

2:00 pm Targeting the Hippo Pathway in Cancer

  • Anwesha Dey Principal Scientist, Discovery Oncology, Genentech

2:30 pm Afternoon Break & Poster Session

Synopsis

As the landscape of innovative discovery, translation and development efforts to target the Hippo pathway for therapeutic application expands, it is more important thanmever to collaborate and learn with your peers as we continue to advance landscape of Hippo targeted therapies. Join our dedicated session to share your latest data and have a first look about what your peers are working on!

3:30 pm Hippo-YAP1 Deregulation in Cancer: Opportunity & Challenges for Drug Discovery

Synopsis

• Hippo-YAP1 deregulation in cancer
• Recent advancements in drug discovery
• Challenges and unknowns

4:00 pm Targeting TEAD Hydrophobic Pocket for Cancer Therapy or Regenerative Medicine

  • WanJin Hong Professor & Executive Director, Institute of Molecular and Cell Biology, A*STAR

Synopsis

  • TEAD transcriptional factors are downstream effectors of Hippo pathway
  • We discovered that TEADs have a druggable hydrophobic pocket
  • We identified several chemical compounds targeting the TEAD hydrophobic pocket
  • Targeting TEADs represents a novel revenue for drug development

4:30 pm Chair’s Closing Remarks

  • Jason Faris Senior Clinical Program Leader, Novartis Institutes for BioMedical Research

4:45 pm End of Conference Day One